Neuberg becomes the first lab chain of Indian origin to start direct operations in the USA with CLIA-certified lab operations
Neuberg Diagnostics has launched its clinical laboratory operations in North Carolina in the United States of America (USA). The laboratory in North Carolina, known as the Neuberg Centre for Genomic Medicine (NCGM), will focus on genomic and molecular testing based on new-generation sequencing techniques. It also runs an extensive network of labs in India, South Africa and the United Arab Emirates (UAE) as well.
NCGM has introduced COVID-19 molecular testing to detect active SARS CoV-2 virus infection that is of immediate public health priority in North America, along with genome-scale testing, such as Exome Sequencing, which is applicable across a variety of Rare Genetic Disease Testing (inherited diseases) from new-born screening to oncology to paediatric care setting.
Speaking on the launch, Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics, said, “NCGM, USA will act as the laboratory and hub, aiding our operations in North America. Through leveraging our collaborative efforts across our organisation in India, South Africa and the UAE, and with our external partners, we aim to develop and provide the best-in-class affordable tests. As they are deployed, the accessibility and affordability of the tests will reduce disparity and benefit individuals across the board.”
Adding to it, Dr Andy Bhattacharjee, CEO, NCGM, USA, said, “The setup has a comprehensive genomic testing facility allowing large-scale clinical and research projects. With the capacity to conduct more than 400 variety of tests, the centre will conduct large-scale clinical diagnostics and genomics projects with greater sample volumes at an unprecedented depth and coverage of the genome. Currently, we are offering COVID RT-PCR testing services at our NC Lab with home sample collection facilities in association with FexEx to help fight the pandemic in the USA too.”